Talecris Biotherapeutics, former Bayer maker of plasma-derived protein therapies LBO'd by Cerberus, will see its quiet period end on Nov. 9. On September 30, 2009, the company raised $950 million by offering 50 million shares at $19.00, within the expected range of $18.00 to $20.00. Morgan Stanley, Goldman Sachs, and Citi acted as lead managers on the deal.
